BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

Summary

This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells were investigated as a single agent in multiple myeloma

Timeline

Start

2020-07-23

Primary completion

2025-04-29

Completion

2025-04-29

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications